Danaher Corporation vs Lam Research Corporation — how do they compare? Danaher Corporation trades at $200 (market cap $140.88B), while Lam Research Corporation trades at $354 (market cap $432.82B). The key difference: Lam Research Corporation is far larger — about 3.1× Danaher Corporation's market cap, and Danaher Corporation pays the higher dividend (0.8%). Which is the better fit depends on your goals.
| DHR | LRCX | |
|---|---|---|
Market Cap | $140.88B | $432.82B |
Sector | Health | Technology |
52-Week High | $242.05 | $433.33 |
52-Week Low | $161.91 | $94.84 |
Enterprise Value | $153.66B | $431.81B |
Dividend Yield | 0.8% | 0.3% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Lam Research (LRCX) trades at $329.92, down 5.83% amid broader semiconductor sector volatility. The stock shows strong fundamentals with Q1 2026 EPS of $1.47 beating estimates by 8%, marking the third consecutive quarterly beat. Revenue grew 23.8% year-over-year to $18.44B in 2025, while net income margin expanded to 30.94%. Technical indicators show bearish momentum with the stock trading below key resistance at $332, though RSI at 22.63 suggests potential oversold conditions. Recent news highlights AI-driven demand for semiconductor equipment as a key growth catalyst.
LRCX presents a compelling long-term opportunity with 78% analyst buy ratings and $393 consensus price target (19% upside), though elevated P/E of 62.37 warrants caution. Strong cash flow generation ($6.17B operating cash flow) supports dividend payments and strategic investments. Risks include semiconductor cycle volatility and competitive pressures, but AI infrastructure spending provides durable tailwinds for the wafer fabrication equipment leader.
Trailing returns across standard periods
Latest headlines on both assets
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →